University of Khartoum

Immunochemotherapy of persistent postkala- azar dermal leishmaniasis: a novel approach to treatment

Immunochemotherapy of persistent postkala- azar dermal leishmaniasis: a novel approach to treatment

Show full item record

Title: Immunochemotherapy of persistent postkala- azar dermal leishmaniasis: a novel approach to treatment
Author: Musa, Ahmed M.; Khalil, Eltahir Awad G.; Mahgoub, Fawzi Abd Elrahim; Hassab, Sara Hamad; Elkadarud, Abd Elgadir Mohamed Yousif
Abstract: Post-kala-azar dermal leishmaniasis (PKDL) is a recognized dermatosis that follows successful treatment of visceral leishmaniasis in the Sudan. This randomized and doubleblind study aimed to assess safety, immunogenicity and curative potentials of a novel immunochemotherapy regimen in patients with persistent PKDL. Following informed consent, 30 patients were randomized to receive alum-precipitated autoclaved Leishmania major (Alum/ALM) vaccine + Bacille Calmette-Gu´erin (BCG) and sodium stibogluconate (SSG) or vaccine diluent and SSG. The SSG+Alum/ALM+BCG proved safe with minimal local adverse events. In the SSG+vaccine group, 87% of the patients were cured by day 60 compared with 53% in the SSG alone group (SSG+vaccine efficacy = 71%, 95% CI for risk ratio 0.7—1.16). On day 90 of follow-up there were two relapses in the SSG alone arm and none in the SSG+vaccine arm. Pretreatment cytokines showed high IFN- or high IFN- /IL-10 levels and leishmanin skin test (LST) non-reactivity, while healing/clinical improvement were associated with LST reactivity and low
URI: http://khartoumspace.uofk.edu/123456789/17040
Date: 2015-11-12


Files in this item

Files Size Format View

This item appears in the following Collection(s)

Show full item record

Share

Search DSpace


Browse

My Account